Currently viewing the category: "Topotarget"

Topotarget, results keep rolling in

By On 14. June 2012 · Leave a Comment · In Topotarget

Practically every day these weeks, new surveys and studies are being published about Belinostat. Today,  a study regarding the effect of belinostat in International Journal of Gynecological Cancer titled:

Phase II Activity of Belinostat (PXD-101), Carboplatin, and Paclitaxel in Women With Previously Treated Ovarian Cancer

Conclusions: Belinostat, carboplatin, and paclitaxel combined was reasonably […]

Continue Reading →

TopoTarget ‘s Belinostat effective in pancreatic cancer

By On 13. June 2012 · Leave a Comment · In Topotarget

Last week saw the publication of a paper on TopoTarget ‘s Berlinostat in Pancreatic Cancer. The paper was accepted  after clarification on some of the points mentioned by the reviewer –

The combination of belinostat and gemcitabine has some additive effect in vitro, yet not synergic nor significant neither confirmed by in vivo experiments.

In […]

Continue Reading →

Topotarget – data coming in less than 3 weeks

By On 12. June 2012 · Leave a Comment · In Topotarget

 

By popular demand – we are including TopoTarget in the Medicoinvestor universe.. apparently important data is coming within 3 weeks.

We hope that loads of interesting analytic posts – (of quality and some substance 🙂  ) about TopoTarget will find their way to Medicoinvestor.

Druen and I have very limited knowledge regarding TopoTarget – […]

Continue Reading →

Danske aktier

By On 7. May 2011 · Leave a Comment · In BioPorto, Coloplast, DanDrit, Exiqon, Genmab, Topotarget, Veloxis, Zealand
Continue Reading →
Set your Twitter account name in your settings to use the TwitterBar Section.